OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
6029$211.0057

Artra Group Corp

Healthcare Facilities & ServicesVerified

Artra Group Corp has a market price of 211 JPY per share, with a market capitalization of 2,166,280,874 JPY. The company's price-to-book ratio is 1.53, and its price-to-tangible-book ratio is also 1.53, indicating that the market values the company slightly above its book value. The enterprise value to EBITDA ratio is negative at -77.81, reflecting the company's current operating losses. The enterprise value to revenue ratio is 2.36, suggesting that the company is valued at a moderate multiple of its revenue. The company's profitability metrics are weak, with a return on equity of -2.47% and a return on assets of -0.83%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -31,649,000 JPY, and the net income is also negative at -34,900,000 JPY. The company's debt-to-equity ratio is 1.02, suggesting that it is financed almost equally by debt and equity. The current ratio of 1.88 indicates that the company has sufficient current assets to cover its current liabilities. Artra Group Corp's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the period is 1,043,350,000 JPY, with a gross profit of 320,813,000 JPY. The company's operating and net losses suggest that it is not currently profitable and may be facing challenges in its core operations. The company's growth trajectory is uncertain, with no disclosed revenue growth or expansion plans. The company's operating and net losses indicate that it is not currently generating positive cash flows from operations. The company's liquidity position is medium, with a current ratio of 1.88, but its net cash position is negative after subtracting total debt. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges in the near term. The company's operating and net losses indicate that it is not currently profitable and may need to raise additional capital to fund its operations. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations. The company's recent financial performance, as reported in its latest financial statements, shows a revenue of 1,043,350,000 JPY and a gross profit of 320,813,000 JPY. The company's operating income is negative at -31,649,000 JPY, and its net income is also negative at -34,900,000 JPY. The company's liquidity position is medium, with a current ratio of 1.88, but its net cash position is negative after subtracting total debt. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations.

30-day price · 6029(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyArtra Group Corp
Ticker6029.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Artra Group Corp is a Japanese biotechnology company that provides healthcare services and equipment, primarily operating in the healthcare facilities and services industry.

Classification. Artra Group Corp is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92.

Artra Group Corp has a market price of 211 JPY per share, with a market capitalization of 2,166,280,874 JPY. The company's price-to-book ratio is 1.53, and its price-to-tangible-book ratio is also 1.53, indicating that the market values the company slightly above its book value. The enterprise value to EBITDA ratio is negative at -77.81, reflecting the company's current operating losses. The enterprise value to revenue ratio is 2.36, suggesting that the company is valued at a moderate multiple of its revenue. The company's profitability metrics are weak, with a return on equity of -2.47% and a return on assets of -0.83%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -31,649,000 JPY, and the net income is also negative at -34,900,000 JPY. The company's debt-to-equity ratio is 1.02, suggesting that it is financed almost equally by debt and equity. The current ratio of 1.88 indicates that the company has sufficient current assets to cover its current liabilities. Artra Group Corp's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's total revenue for the period is 1,043,350,000 JPY, with a gross profit of 320,813,000 JPY. The company's operating and net losses suggest that it is not currently profitable and may be facing challenges in its core operations. The company's growth trajectory is uncertain, with no disclosed revenue growth or expansion plans. The company's operating and net losses indicate that it is not currently generating positive cash flows from operations. The company's liquidity position is medium, with a current ratio of 1.88, but its net cash position is negative after subtracting total debt. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may face liquidity challenges in the near term. The company's operating and net losses indicate that it is not currently profitable and may need to raise additional capital to fund its operations. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations. The company's recent financial performance, as reported in its latest financial statements, shows a revenue of 1,043,350,000 JPY and a gross profit of 320,813,000 JPY. The company's operating income is negative at -31,649,000 JPY, and its net income is also negative at -34,900,000 JPY. The company's liquidity position is medium, with a current ratio of 1.88, but its net cash position is negative after subtracting total debt. The company's debt-to-equity ratio of 1.02 suggests that it is using a significant amount of debt to finance its operations.
Key takeaways
  • Artra Group Corp is currently unprofitable, with a negative return on equity and return on assets.
  • The company's liquidity position is medium, with a current ratio of 1.88, but its net cash position is negative after subtracting total debt.
  • The company's debt-to-equity ratio is 1.02, indicating a significant reliance on debt financing.
  • The company's enterprise value to EBITDA ratio is negative, reflecting its current operating losses.
  • The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification.
  • The company's risk assessment indicates a medium liquidity risk and a low dilution risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$1.04B
Gross profit$320.8M
Operating income-$31.6M
Net income-$34.9M
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets$4.20B
Total liabilities$2.79B
Total equity$1.41B
Cash & equivalents$1.14B
Long-term debt$1.44B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$3.16B-$375.5M-$351.1M-$281.6M
FY-3$4.67B$2.8M$2.1M-$7.5M
FY-2$4.50B$31.1M$54.0M$70.4M
FY-1$4.23B-$25.6M-$36.7M$39.1M
FY0$3.93B$139.3M$258.3M$285.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$5.60B$1.44B$1.84B
FY-3$4.65B$1.31B$1.23B
FY-2$4.57B$1.45B$1.14B
FY-1$4.11B$1.44B$1.05B
FY0$4.13B$1.70B$1.13B
PeriodOCFCapExFCFSBC
FY-4-$208.6M-$56.2M-$281.6M
FY-3-$132.6M-$156.4M-$7.5M
FY-2$217.8M-$123.6M$70.4M
FY-1$200.9M-$78.5M$39.1M
FY0$275.2M-$78.2M$285.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$1.04B-$31.6M-$34.9M
FQ-6$1.01B-$25.8M-$28.7M
FQ-5$1.03B-$12.3M-$14.6M
FQ-4$1.15B$44.1M$41.5M
FQ-3$979.7M-$19.9M-$19.7M
FQ-2$903.7M$44.0M$135.3M
FQ-1$944.5M$63.2M$63.3M
FQ0$1.10B$51.9M$79.4M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$4.20B$1.41B$1.14B
FQ-6$4.06B$1.40B$914.1M
FQ-5$3.94B$1.39B$966.0M
FQ-4$4.11B$1.44B$1.05B
FQ-3$3.83B$1.42B$1.02B
FQ-2$3.81B$1.55B$1.02B
FQ-1$3.86B$1.61B$1.10B
FQ0$4.13B$1.70B$1.13B
PeriodOCFCapExFCFSBC
FQ-7
FQ-6$9.7M-$42.8M
FQ-5
FQ-4$200.9M-$78.5M
FQ-3
FQ-2$4.4M-$42.0M
FQ-1
FQ0$275.2M-$78.2M
Valuation
Market price$211.00
Market cap$2.17B
Enterprise value$2.46B
P/E
Reported non-GAAP P/E
EV/Revenue2.4
EV/Op income
EV/OCF
P/B1.5
P/Tangible book1.5
Tangible book$1.41B
Net cash-$296.2M
Current ratio1.9
Debt/Equity1.0
ROA-0.8%
ROE-2.5%
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
Metric6029Activity
Op margin-3.0%5.6% medp25 -4.2% · p75 12.6%below median
Net margin-3.3%2.8% medp25 -3.4% · p75 8.8%below median
Gross margin30.7%36.5% medp25 23.7% · p75 65.2%below median
CapEx / revenue-4.9% medp25 -11.5% · p75 -2.0%
Debt / equity102.0%69.3% medp25 7.9% · p75 120.9%above median
Observations
IR observations
Last actual EPS25.16 JPY
Last actual revenue3,927,220,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:51 UTC#1787c99c
Market quoteclose JPY 182.00 · shares 0.01B diluted
no public URL
2026-05-05 00:51 UTC#4cd8ddad
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 00:53 UTCJob: a4097f96